Study of the Efficacy and Safety of Bupivacaine TTS Patch in Patients With Chronic Low Back Pain

PHASE2CompletedINTERVENTIONAL
Enrollment

263

Participants

Timeline

Start Date

March 31, 2010

Primary Completion Date

February 28, 2011

Study Completion Date

February 28, 2011

Conditions
Chronic Low Back Pain
Interventions
DRUG

Bupivacaine TTS (Bupivacaine Patch)

Contains bupivacaine base, in a flexible and rectangular-shaped, transdermal, delivery system. Three patches applied to the lower back every 72 hours for 12 weeks.

DRUG

Placebo patch

Identical in size and shape to the Bupivacaine Patch. Three patches applied to the lower back every 72 hours for 12 weeks.

Trial Locations (21)

10004

New York

16602

Altoona

18103

Allentown

19139

Philadelphia

23294

Richmond

27103

Winston-Salem

30060

Marietta

30265

Newnan

32605

Gainesville

32779

Longwood

33306

Fort Lauderdale

33409

West Palm Beach

63141

St Louis

73109

Oklahoma City

75231

Dallas

77074

Houston

78756

Austin

85283

Tempe

90502

Torrance

91942

La Mesa

01103

Springfield

Sponsors

Lead Sponsor

Collaborators (1)

All Listed Sponsors
collaborator

Pfizer

INDUSTRY

lead

Durect

INDUSTRY

NCT01096966 - Study of the Efficacy and Safety of Bupivacaine TTS Patch in Patients With Chronic Low Back Pain | Biotech Hunter | Biotech Hunter